NDAINJECTIONINJECTABLE
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GEREF (sermorelin acetate) is a synthetic growth hormone-releasing hormone (GHRH) analog administered by injection to stimulate endogenous growth hormone secretion. It is indicated for the diagnosis of growth hormone deficiency in children and adults. The drug works by binding to GHRH receptors on anterior pituitary somatotroph cells to promote GH release.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on lifecycle management and cost containment rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GEREF offers stability in a mature, established therapeutic area but limited growth upside due to LOE proximity. Roles emphasize commercial optimization, payer negotiations, and lifecycle extension strategies rather than launch excitement or indication expansion.
Brand ManagerMarket Access Manager
Worked on GEREF at EMD Serono Research & Development Institute, Inc.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.